Open | - |
Close | - |
Volume / Avg. | 1.024K / 2.074M |
Day Range | - - - |
52 Wk Range | 0.681 - 2.970 |
Market Cap | $368.627M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 49 |
Short Interest | 1.95% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Adverum Biotechnologies (NASDAQ: ADVM) through any online brokerage.
Other companies in Adverum Biotechnologies’s space includes: Precigen (NASDAQ:PGEN), Inozyme Pharma (NASDAQ:INZY), Adaptimmune Therapeutics (NASDAQ:ADAP), Anika Therapeutics (NASDAQ:ANIK) and TScan Therapeutics (NASDAQ:TCRX).
The latest price target for Adverum Biotechnologies (NASDAQ: ADVM) was reported by RBC Capital on Tuesday, March 19, 2024. The analyst firm set a price target for 2.00 expecting ADVM to rise to within 12 months (a possible 12.40% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Adverum Biotechnologies (NASDAQ: ADVM) is $1.7794 last updated Today at March 19, 2024 at 7:40 AM EDT.
There are no upcoming dividends for Adverum Biotechnologies.
Adverum Biotechnologies’s Q1 earnings are confirmed for Thursday, May 9, 2024.
The stock split for ADVM was announced on Tuesday, March 19, 2024. The date this stock split will start trading, also known as the ex-date, will be on Thursday, March 21, 2024.
Adverum Biotechnologies is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.